Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in... see more

Recent & Breaking News (NDAQ:VNDA)

Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

PR Newswire June 19, 2015

Vanda Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference

PR Newswire June 2, 2015

Vanda Receives Innovation Award from the National Organization for Rare Disorders for Development of HETLIOZ®

PR Newswire May 26, 2015

Vanda Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference

PR Newswire May 11, 2015

Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results

PR Newswire May 6, 2015

American Foundation for the Blind Announces 2015 Helen Keller Achievement Award Honorees

PR Newswire May 6, 2015

Vanda Receives Positive CHMP Opinion for HETLIOZ® (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder in the European Union

PR Newswire April 24, 2015

Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015

PR Newswire April 16, 2015

Vanda Announces Trial Date for Fanapt® Patent Cases

PR Newswire April 13, 2015

Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book

PR Newswire April 9, 2015

Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis

PR Newswire March 4, 2015

Vanda Pharmaceuticals Reports Fourth Quarter 2014 and Full Year 2014 Financial Results

PR Newswire February 19, 2015

Vanda Pharmaceuticals to Announce Fourth Quarter 2014 Financial Results on February 19, 2015

PR Newswire February 2, 2015

Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day

PR Newswire January 29, 2015

Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book

PR Newswire January 16, 2015

Vanda to regain US and Canadian rights to Fanapt®

PR Newswire December 22, 2014

Vanda Pharmaceuticals to Present at the 26th Annual Piper Jaffray Healthcare Conference

PR Newswire December 1, 2014

Idera Pharmaceuticals Names Vincent J. Milano Chief Executive Officer

GlobeNewswire December 1, 2014

Vanda Pharmaceuticals to Present at the Stifel Nicolaus 2014 Healthcare Conference

PR Newswire November 18, 2014

Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock

PR Newswire October 29, 2014